Fig. 2.

Limitations and potential approaches of first-line atezolizumab plus bevacizumab combination therapy for HCC. Subgroups of advanced HCC patients falling into the treatment criteria of first-line atezolizumab plus bevacizumab therapy may be further selected based on superior or nonsuperior OS when compared to first-line sorafenib therapy. The dose of atezolizumab and bevacizumab may be adjusted according to clinical studies in the indicated ranges. A composite biomarker consisting of three types is likely needed to guide patient selection and therapeutic course.